Please login to the form below
American Heart Association meeting
This page shows the latest American Heart Association meeting news and features for those working in and with pharma, biotech and healthcare.
The Medicines Company surges on rumours of Novartis takeover
Novartis isn’t commenting on the speculation, but Bloomberg analyst Sam Fazeli says that inclisiran would slot neatly into the Swiss group’s cardiovascular portfolio alongside Entresto (sacubitril/valsartan), its heart ... At the American Heart
Latest news
-
TMC preps filings for inclisiran after final phase 3 trials hit the mark
The ORION-9 and ORION-10 data will be reported in full at the American Heart Association (AHA) meeting in November.
-
AZ says target of $45bn sales by 2023 still achievable
The product has new cardiovascular outcomes data from the DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association (AHA) ... It will be followed by additional studies in patients
-
Amgen's Repatha unclogs blocked arteries, says study
At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of
-
Sanofi plans 18 new product launches by 2020
These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to
-
PCSK9 inhibitor alirocumab works in statin-intolerance
Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... The ODYSSEY ALTERNATIVE trial - reported
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
Research Partnership
Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
